ImmusanT publishes positive data from Phase 1 trials of Nexvax2 in celiac disease patients

(MacDougall Biomedical Communications, Inc.) ImmusanT announces the publication of positive data from Phase 1 clinical trials of the Nexvax2 therapeutic vaccine in celiac disease patients in The Lancet Gastroenterology and Hepatology.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news